Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)

Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)

ABSTRACT Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as Nonalcoholic fatty liver disease (NAFLD), is one of the most common hepatic diseases in individuals with overweight or obesity. In this context, a panel of experts from three medical societi...

Full description

Bibliographic Details
Main Authors:	Rodrigo Oliveira Moreira, Cynthia Melissa Valerio, Cristiane Alves Villela-Nogueira, Cintia Cercato, Fernando Gerchman, Ana Maria Pita Lottenberg, Amélio Fernando Godoy-Matos, Ricardo de Andrade Oliveira, Carlos Eduardo Brandão Mello, Mário Reis Álvares-da-Silva, Nathalie Carvalho Leite, Helma Pinchemel Cotrim, Edison Roberto Parisi, Giovanni Faria Silva, Paulo Augusto Carvalho Miranda, Bruno Halpern, Claudia Pinto Oliveira
Format:	Article
Language:	English
Published:	Brazilian Society of Endocrinology and Metabolism 2023-12-01
Series:	Archives of Endocrinology and Metabolism
Subjects:	Clinical guidelines overweight obesity non-alcoholic fatty liver disease metabolic dysfunction-associated steatotic liver disease
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972023000601000&lng=en&tlng=en

Similar Items

Proposal of an obesity classification based on weight history: an official document by the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society for the Study of Obesity and Metabolic Syndrome (ABESO)
by: Bruno Halpern, et al.
Published: (2022-04-01)

2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes
by: Amélio F. Godoy-Matos, et al.
Published: (2024-01-01)

“Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
by: Bruno Halpern, et al.
Published: (2023-10-01)

From NAFLD to MASLD: When metabolic comorbidity matters
by: Shan Hong, et al.
Published: (2024-03-01)

Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Avneet Singh, et al.
Published: (2024-02-01)

Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM)
by: Marcello Casaccia Bertoluci, et al.
Published: (2017-07-01)

Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Soyeon Shin, et al.
Published: (2023-12-01)

Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
by: Shuhei Fukunaga, et al.
Published: (2024-01-01)

Position statement on nutrition therapy for overweight and obesity: nutrition department of the Brazilian association for the study of obesity and metabolic syndrome (ABESO—2022)
by: Renata Bressan Pepe, et al.
Published: (2023-06-01)

Consensus - reference ranges of vitamin D [25(OH)D] from the Brazilian medical societies. Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC/ML) and Brazilian Society of Endocrinology and Metabolism (SBEM)
by: Carlos Eduardo S. Ferreira, et al.
Published: (2017-11-01)

Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study
by: Michihiro Iwaki, et al.
Published: (2024-04-01)

Reference values of 25-hydroxyvitamin D revisited: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC)
by: Carolina Aguiar Moreira, et al.
Published: (2020-06-01)

GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN GASTROINTESTINAL AND LIVER DISEASES: PROCEEDINGS OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN NUCLEUS FOR THE STUDY OF HELICOBACTER PYLORI AND MICROBIOTA (NBEHPM), AND BRAZILIAN FEDERATION OF GASTROENTEROLOGY (FBG)
by: Ricardo Correa BARBUTI, et al.
Published: (2020-11-01)

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
by: Joo Hyun Oh, et al.
Published: (2024-04-01)

Salt-Intake-Related Behavior Varies between Sexes and Is Strongly Associated with Daily Salt Consumption in Obese Patients at High Risk for MASLD
by: Bianca Heller, et al.
Published: (2023-09-01)

Template for the laboratory’s report of 25-hydroxyvitamin D: recommendations form the Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC/ML) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
by: Carlos Eduardo S. Ferreira, et al.

Brazilian Society of Hepatology and Brazilian College of Radiology practice guidance for the use of elastography in liver diseases
by: Ana Carolina Cardoso, et al.
Published: (2021-05-01)

Targeting the Adipose Tissue–Liver–Gut Microbiota Crosstalk to Cure MASLD
by: Daniela Gabbia, et al.
Published: (2023-11-01)

Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis
by: Christian Stoess, et al.
Published: (2023-08-01)

Influence of Sugar-Sweetened Beverages Intake on Sarcopenic Obesity, Visceral Obesity, and Sarcopenia in Lebanese Patients with MASLD: A Case-Control Study
by: Maha Hoteit, et al.
Published: (2024-03-01)

Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis – A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso)
by: Miguel Madeira, et al.
Published: (2020-10-01)

Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project
by: Katarzyna Nabrdalik, et al.
Published: (2023-11-01)

Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study
by: Adelaida Solomon, et al.
Published: (2023-10-01)

MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
by: Anju G. S. Phoolchund, et al.
Published: (2024-01-01)

Brazilian Society of Hepatology and Brazilian Society of Infectious Diseases Guidelines for the Diagnosis and Treatment of Hepatitis B
by: Maria Lucia Ferraz, et al.
Published: (2020-09-01)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
by: Gi-Ae Kim, et al.
Published: (2023-10-01)

Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO)
by: Barbara C. Silva, et al.
Published: (2022-10-01)

Prevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study
by: Jesús Rivera-Esteban, et al.
Published: (2023-11-01)

Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)
by: João Roberto M. Martins, et al.
Published: (2021-01-01)

An Optimized Strategy Based on Conventional Ultrasound for Diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Xiongcai Feng, et al.
Published: (2023-11-01)

Emerging therapies for MASLD and their impact on plasma lipids
by: Madison Nguyen, et al.
Published: (2024-03-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
by: Katharina Staufer, et al.
Published: (2023-07-01)

Approach to adult patients with primary hypothyroidism in some special situations: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)
by: Gláucia Maria Ferreira da Silva Mazeto, et al.
Published: (2022-11-01)

Screening for social determinants of health among populations at risk for MASLD: a scoping review
by: Rebecca G. Kim, et al.
Published: (2024-04-01)

Effects of an Eight Week Very Low-Calorie Ketogenic Diet (VLCKD) on White Blood Cell and Platelet Counts in Relation to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Subjects with Overweight and Obesity
by: Sara De Nucci, et al.
Published: (2023-10-01)

Treatment strategies for low-risk papillary thyroid carcinoma: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)
by: Laura Sterian Ward, et al.
Published: (2022-09-01)

RECOMMENDATIONS FOR INVASIVE PROCEDURES IN PATIENTS WITH DISEASES OF THE LIVER AND BILIARY TRACT: REPORT OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN SOCIETY OF DIGESTIVE ENDOSCOPY (SOBED) AND BRAZILIAN SOCIETY OF INTERVENTIONAL RADIOLOGY AND ENDOVASCULAR SURGERY (SOBRICE)
by: Leonardo de Lucca SCHIAVON, et al.

What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside
by: Pojsakorn Danpanichkul, et al.
Published: (2024-01-01)

Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma
by: Chen P, et al.
Published: (2024-03-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
by: Wayne Eskridge, et al.
Published: (2023-09-01)